> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Determined for Giapreza
- URL: https://www.fdaweb.com/review-period-determined-for-giapreza/
- Published: 2019-09-06T12:00:00.000Z
- Updated: 2026-09-15T01:48:15.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144936

*Federal Register* notice: FDA has determined the regulatory review period for patent extension purposes for La Jolla Pharmaceutical’s Giapreza (angiotensin II), a vasoconstrictor for increasing blood pressure in adults with septic or other distributive shock. The review period is 1,639 days, which includes 1,463 days that occurred during the testing phase and 176 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-09-05/pdf/2019-19110.pdf?ref=fdaweb.com).